Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.